The present study found that the fifth epidermal growth factor-like domain of thrombomodulin (TME5) possesses the cytoprotective function in association with an increase in levels of anti-apoptotic myeloid cell leukemia-1 protein in an activated protein C-independent manner in human umbilical vein endothelial cells (HUVECs). Importantly, TME5 counteracted calcineurin inhibitor-induced vascular permeability and successfully prevented monocrotaline-induced sinusoidal obstruction syndrome (SOS) in a murine model. Taken together, TME5 may be useful for preventing or treating lethal complications that develop after hematopoietic stem cell transplantation such as SOS and thrombotic microangiopathy in which endothelial cell damage has a role.
INTRODUCTION
Thrombomodulin (TM) is a glycosylated type I transmembrane molecule with multiple domains that include an NH 2 -terminal lectin-like region, six tandem epidermal growth factor (EGF)-like structures, an O-glycosylation site-rich domain, a transmembrane domain and a cytoplasmic tail domain ( Figure 1 ). 1 TM is ubiquitously expressed on endothelial cells and binds to thrombin, forming a 1:1 complex via the fourth and fifth regions of an EGF-like domain (TME45) and acting as an anticoagulant. 2 In addition, the thrombin-TM complex activates protein C to produce activated protein C (APC), which inactivates factors VIIIa and Va in the presence of protein S, thereby inhibiting further thrombin formation. 3 The minimum structure that is essential for generating APC is localized in TME456 repeats of the EGF-like domain ( Figure 1 ). 4 Interestingly, TM possesses anti-inflammatory properties; the lectin-like domain of TM binds to and inactivates high-mobility group box 1 protein (HMGB1), a nuclear architectural chromatin-binding protein that stimulates production of inflammatory cytokines such as interleukin 6 (IL-6) and TNF-α via toll-like receptor 4 and the receptor for advanced glycation end products after being released from necrotic cells or secreted from inflammatory cells such as activated macrophages. 5 In addition, the lectin-like domain of TM inhibits lipopolysaccharide-induced cytokine production and adhesion of neutrophils to endothelial cells in association with suppression of extracellular signal-regulated kinase (ERK) and nuclear factor κB (NF-κB). 6 Intriguingly, TM exerts endothelial cytoprotective effects against inflammatory cytokines and calcineurin inhibitors such as cyclosporine A (CsA) and tacrolimus (FK506) via upregulation of myeloid cell leukemia sequence 1 (Mcl-1) proteins in a process that is mediated by the ERK signal transduction pathway. 7 This cytoprotective effect is also mediated by TME45 and is independent of APC ( Figure 1 ). 7 Interestingly, TME45 also stimulates proliferation of human umbilical vein endothelial cells (HUVECs) and promotes angiogenesis in vivo. 7 Recombinant human soluble TM (rTM) includes the active, extracellular domain of TM and inactivates coagulation. Use of rTM for the treatment of disseminated intravascular coagulation was approved in Japan in 2008, and we have since rescued individuals with disseminated intravascular coagulation complicated by various underlying diseases, including transplantation-associated microangiopathy (TMA) and sinusoidal obstruction syndrome (SOS), as well as engraftment syndrome following hematopoietic stem cell transplantation (HSCT). [8] [9] [10] The pathogenesis of these potentially lethal complications is based on endothelial damage. Thus, they are referred to as endothelial syndromes. 11 Use of rTM for treatment of coagulopathy that develops after HSCT significantly prolongs overall survival of patients compared to those with coagulopathy who did not receive rTM mainly because rTM improves the survival of patients with endothelial syndrome that triggers coagulopathy at day 100 after HSCT.
12 rTM appears to be relatively safe, as a phase III clinical trial comparing the efficacy and safety between rTM and low-dose heparin showed that the incidence of bleeding-related adverse events up to 7 days after the start of infusion was lower in the rTM group than in the heparin group (43.1 vs 56.5%, P = 0.0487), although this clinical trial did not include patients who received HSCT. 13 Notably, one patient with SOS after HSCT developed a fatal intracranial hemorrhage during treatment with rTM.
14 These observations prompted us to develop a novel agent that does not affect the coagulation system to safely prevent or treat endothelial syndrome after HSCT.
The present study attempted to identify the minimum structure of TME45 that is responsible for the cytoprotective function of TM and explored the potential of polypeptides comprising this structure as a cytoprotective agent in vitro and in vivo.
MATERIALS AND METHODS Cells
HUVECs were purchased from Lonza Walkersville Inc. (Basel, Switzerland) and cultured in EBM-2 culture medium supplemented with EGM-2 endothelial cell growth factors (Lonza Walkersville Inc.). Human endothelial EA.hy926 cells were purchased from ATCC (Manassas, VA, USA) and cultured with DMEM (Sigma-Aldrich, St Louis, MO, USA).
Reagents
rTM was provided by Asashi Kasei Pharma (Tokyo, Japan). CsA, FK506, monocrotaline (MCT) and IL-1β were purchased from Sigma-Aldrich.
Generation of TME5
The fifth EGF-like domain of TM (TME5) was synthesized and cloned into the pcDNA3.1/V5-His-A expression vector (Invitrogen, Carlsbad, CA, USA) and pPICZα A expression vector (Invitrogen). These vectors were transfected into either COS-1 cells or Pichia pastoris strain SMD1163 (his4 pep4 prb1), 15 respectively. For Pichia expression, the DNA coding region for TME5 was synthesized according to the preferred codon usage of the methylotrophic yeasts 16 and the transformant cells were grown to highcell density on methanol medium. 16 The generated TME5 proteins were purified with a His-tagged protein purification kit (MBL, Aichi, Japan) or Ni Sepharose 6 Fast Flow (GE Healthcare, Little Chalfont, UK). The TME5 polypeptide was synthesized by Peptide Institute Inc. (Osaka, Japan).
Plasmids and production of proteins D123 comprising the extracellular domain of TM and D1 comprising the lectin-like domain of TM and TME45 were cloned into the FLAG-TEV-tagged pcDNA3.1/V5-His-TOPO expression vector (Invitrogen). COS-1 cells were transfected with each vector, and His-tagged mutant TM proteins were purified using the His-tagged protein purification kit (MBL) as described previously.
7 GPR15 cDNA was purchased from the Mammalian Gene Collection (BC069437) and amplified by PCR. The product was cloned into the pLenti6.3/V5-TOPO vector (Invitrogen) and transduced into HUVECs.
Proliferation assays
HUVECs (5 × 10 3 cells) were cultured in a 96-well plate for 24 h in the presence of the indicated reagent. Bromodeoxyuridine (10 μM/well) was added and incubated for an additional 4 h. The quantity of bromodeoxyuridine incorporated into the newly synthesized DNA was assessed in accordance with the manufacturer's protocol (Roche, Basel, Switzerland).
Blocking antibodies
Antibodies from the TM-specific antibody clone RTM96 (Hycult Biotech Inc., Plymouth Meeting, PA, USA) and clone Phx-01 (Ab24595, Abcam, Cambridge, MA, USA) were used as blocking antibodies to the fourth and fifth region of the EGF-like domain of TM, respectively.
Western blot analysis
Western blot analysis was performed as described previously. 17 The membrane was probed sequentially with the antibodies. Antibodies specific to p-ERK (T202/Y204) (Cell Signaling Technology, Danvers, MA, USA, 9101, 1:1000), ERK (Cell Signaling Technology, 9102, 1:1000), Mcl-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA, sc-819, 1:1000) and GAPDH (Abcam, 1:1000) were used. Band intensities were measured by ImageJ software (Wayne Rasband, NIH).
RNA isolation and reverse transcriptase-PCR
To quantify the expression of Mcl-1, E-selectin and intracellular adhesion molecule 1 (ICAM1), real-time reverse transcriptase-PCR (RT-PCR) was employed as described previously. 18 We measured the expression of 18S for normalization. The primer sequence information for Mcl-1 and 18S was described elsewhere. 7 The primers for PCR to detect E-selectin (5′-AGCTACCCATGGAACACGAC-3′ and 5′-ACGCAAGTTCTCCAGCTGTT-3′) and ICAM1 (5′-TTCACACTGAATGCCAGCTC-3′ and 5′-GTCTGCTGAGACCCC TCTTG-3′) were synthesized by Sigma-Aldrich Japan (Tokyo, Japan).
Vascular permeability assay in vitro
Effects of test agents on vascular permeability were measured with a vascular permeability assay kit (Millipore, Billerica, MA, USA) as described previously. 7 
Apoptosis assay
The ability of a calcineurin inhibitor to induce apoptosis in HUVECs was measured using the annexin V-fluorescein isothiocyanate apoptosis detection kit (Pharmingen, Inc., San Diego, CA, USA) as previously described. 7 Protein C activation assay
The ability of TM to accelerate thrombin-catalyzed protein C activation was measured as previously described. 19 APC hydrolytic activity of S-2366 was monitored at 405 nm. One unit of TM activity was defined as 1 μmol of p-nitroaniline formed/min.
Pharmacokinetics of TME5 in vivo
TME5 (1 mg per kg body weight) was given to ICR mice (6-week-old female) via IP injection. Blood collection was initiated 3 h after injection and continued up to 72 h (3, 6, 12, 24, 48 and 72 h after injection). The collected blood samples were subjected to ELISA to monitor the plasma levels of TME5. 
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The PVC microtiter plate was coated with TM-specific antibody (Abcam, ab6980). An HRP-conjugated TM-specific polyclonal antibody (Bioss, Woburn, MA, USA, bs-0525R-HRP) was used as a secondary antibody.
Murine in vivo endothelial cell damage model
All animal care and experimental procedures were approved by the Institutional Animal Care and Use Committee of Kochi University. C57BL6 mice (6-week-old female) were treated with either FK506 (5 mg per kg body weight) or control diluent (saline) every day for 7 days by IP injection to induce vascular cell damage as previously described. 7 Either TME5 (0.5 mg per kg body weight) or control diluent (double distilled water) was given to mice every other day by IP injection for 7 days. At the end of experiments, mice were killed, and blood was collected. Plasma was separated by centrifugation, and the plasma levels of murine TM, a marker of endothelial cell damage, and fibrin/fibrinogen degradation products (FDPs) were assessed with a murine TM ELISA kit (Uscn Life Science, Tokyo, Japan) and a murine FDP ELISA kit (Uscn Life Science), respectively, following the manufacturer's instructions. At the same time, the kidneys and liver were removed from mice and mashed to make a single-cell suspension. These cells were stained with CD31-specific antibody (Biolegend; 1:1000), and positive cells were isolated by sorting using JSAN (Bay Bioscience, Ltd., Kobe, Japan). RNA was extracted and subjected to real-time RT-PCR to measure the levels of murine Mcl-1.
SOS murine model
ICR mice (6-week-old females) were purchased from Japan SLC, Inc. (Shizuoka, Japan). The treatment protocol followed the rat SOS model with some modifications. 20 Briefly, MCT (200 mg per kg body weight) was administered to mice via IP injection on day 1 to induce SOS. Concurrently, either TME5 (1 mg per kg body weight, n = 6) or control diluent (double distilled water, n = 6) was administered to these mice via IP injection on days 1 and 2. Blood was withdrawn, and plasma levels of aspartate aminotransferase and alanine aminotransferase were measured on day 3 of the experiments. After the blood collection, mice were killed, and the ascites volume was determined. Organs were removed, and paraffinembedded sections were made, stained with hematoxylin and eosin and subjected to pathological examination.
Statistical analysis
Statistical analysis was performed to assess the difference between two groups under multiple conditions using one-way ANOVA followed by Bonferroni multiple comparison tests using PRISM statistical analysis software (GraphPad Software, La Jolla, CA, USA).
RESULTS
The ability of TM to induce Mcl-1 is preserved in TME5 We first utilized a blocking antibody for either TME4 or TME5 to determine which structure is responsible for induction of anti-apoptotic Mcl-1 protein in HUVECs. The blocking antibody for TME5 but not for TME4 hampered the ability of TME45 expressed in COS-1 cells to induce expression of Mcl-1 in HUVECs (Figure 2a) , suggesting that the cytoprotective function of TME45 is preserved in TME5. We next expressed TME5 protein in COS-1 cells and compared its ability to induce Mcl-1 with that of D123 (whole extracellular domain of TM) and TME45. Consistent with a previous study, 7 TME45 (1.5 nM) more potently induced Mcl-1 than D123 (1.5 nM) in HUVECs (Figure 2b ). The ability of TME5 to induce Mcl-1 was almost identical to that of TME45 when used at the equivalent molar concentration (Figure 2b ).
TME5 blocks CsA-induced apoptosis and capillary leakage We next examined whether TME5 possesses anti-apoptotic effects in HUVECs. Following previous experiments, 7 we utilized the calcineurin inhibitor CsA to induce endothelial cell damage in HUVECs. CsA-induced apoptosis was significantly attenuated when HUVECs were cultured with CsA in the presence of TME5 expressed in COS-1 cells; exposure of HUVECs to CsA alone (4 mg/ml) induced a mean of 30% of these cells to become annexin V positive. On the other hand, a mean of 12% of HUVECs became annexin V positive when these cells were exposed to the same concentration of CsA in combination with TME5 expressed in COS-1 cells (0.14 nM) (Figure 3a ). In addition, CsA and IL-1β induced capillary leakage, which was also significantly blocked by TME5 expressed in COS-1 cells in vitro (Figure 3b ).
TME5 stimulates angiogenesis
As rTM stimulates angiogenesis, 7 we explored whether proangiogenic activity is preserved in TME5. Following a previous study, 21 we utilized P. pastoris to generate TME5 protein in large quantities to perform in vivo experiments. Also, we synthesized TME5 polypeptide comprising 40 amino acids and compared their proangiogenic activity in vitro. The synthesized TME5 appeared to possess more potent activity for promoting angiogenesis than Pichia-or COS-1-expressed TME5 or rTM (figure not shown). We therefore decided to utilize synthesized TME5 for further in vivo experiments.
Anticoagulant activity and pharmacokinetics of TME5 TME45 and TME456 bind to thrombin and activate protein C, respectively. 2, 4 We thus assessed whether TME5 was able to generate APC. COS-1 cell-expressed TME45 retained detectable levels of activity to generate APC, although its ability was o 1% in comparison with rTM. Importantly, COS-1 cell-expressed TME5 completely lost the ability to generate APC (Figure 4a ), confirming that TME5 does not affect the anticoagulation system. To determine the dosing schedule in in vivo experiments, we monitored the plasma levels of TME5 after IP injection of 1 mg/kg synthesized TME5 into ICR mice. The plasma levels of TME5 increased steeply and reached a maximum concentration of~8000 ng/mL at 12 h and decreased to basal levels by 72 h with a half-life of 24 h (Figure 4b ). From these observations, we decided to give synthesized TME5 to mice every another day in in vivo experiments.
TME5 prevents tacrolimus (FK506)-induced endothelial injury in vivo
We examined the cytoprotective effect of synthesized TME5 in a FK506-induced endothelial injury murine model. As shown previously, 7 administration of FK506 for 7 days caused endothelial injury as evidenced by an increase in the plasma levels of TM in association with a slight decrease in levels of Mcl-1 in vascular endothelial cells in the kidney and liver (Figures 5a and b) . Plasma levels of FDPs were also increased (Figure 5b) , suggesting that the coagulopathy resulted from endothelial injury. Administration of (Figure 5a ). The FK506-induced increase in plasma levels of TM and FDPs was also hampered when mice received FK506 in combination with synthesized TME5 (Figure 5b ).
TME5 prevents MCT-induced SOS in vivo
Pyrrolizidine alkaloid MCT (200 mg per kg body weight) was given to ICR mice to induce SOS. A dark reddish color, a sign of congestion, was noted on the surface of the liver that was removed from MCT-treated mice 72 h after beginning the experiments (Figure 6a ). Massive ascites was also noted in MCT-treated mice in association with a marked increase in plasma levels of the liver enzymes aspartate aminotransferase and alanine aminotransferase (Figures 6b and c) . Real-time RT-PCR showed that levels of E-selectin and ICAM1, a known endothelial insult marker that is increased in patients who develop SOS after HSCT, 22 were elevated in livers isolated from MCT-treated mice compared with those in control diluent-treated mice (Figure 6d ). In addition, pathological examination showed destructive changes of the liver sinusoid accompanying hemorrhagic necrosis in zone 3 (pericentral zone) and zone 2 (transition zone). Normal structure of central vein was not detectable in zone 3, and sinusoidal dilatation was noted in zone 1 (periportal zone). Collectively, these observations suggested the development of SOS in MCT-treated mice (Figure 6e ). Importantly, when MCT was given to mice together with synthesized TME5, all of these hepatotoxic changes were alleviated (Figures 6a-e) , indicating the prophylactic roles of TME5 against MCT-mediated SOS. On the other hand, the lectin-like domain of TM (D1) known to inhibit ERK/Mcl-1 pathway 7 was not able to counteract MCT-induced ascites retention and elevation of the liver enzymes (data not shown), suggesting the specificity of TME5 against SOS.
DISCUSSION

Endothelial syndrome
11 is a potentially lethal complication after HSCT. Our previous clinical observations showed that the use of rTM successfully rescues individuals with endothelial syndrome [8] [9] [10] and significantly prolongs overall survival of transplant patients with coagulopathy complicated by endothelial syndrome. 12 These observations indicate the cytoprotective roles of rTM in the context of HSCT. Indeed, a recent in vitro study found that TME45 protects endothelial cells from cytokines and calcineurin inhibitor-induced apoptosis, 7 supporting the clinical benefit of rTM for transplant patients. The present study attempted to define the minimal region of TME45 with cytoprotective activity and identified TME5 as a minimum structure (Figure 2) . Intriguingly, the use of TME5 significantly attenuated FK506-and MCT-induced endothelial damage and SOS, respectively, in a murine model (Figures 5 and 6 ). FK506-induced endothelial cell damage is one type of pathogenesis associated with the development of TMA. We therefore assume that the use of TME5 may be useful for preventing or treating TMA. The limitation of this study is the use of MCT to induce SOS in vivo, which is not clinically relevant. Future experiments will evaluate the cytoprotective effects of TME5 in a recently reported SOS model induced by cyclophosphamide and busulfan followed by HSCT. rTM is a potent and relatively safe newly developed anticoagulant. However, we have to be very cautious about hemorrhages when we administer rTM to transplant patients with endothelial syndrome because endothelial syndrome is frequently complicated with transfusion-refractory thrombocytopenia. 24 Importantly, TME5 does not affect the coagulation pathway, as it does not generate APC (Figure 4a ). TME5 may be a suitable cytoprotective agent for transplant patients with a high risk of hemorrhage. Another advantage of TME5 over rTM relates to ERK; TME5 exerts its cytoprotective function via activation of ERK. On the other hand, the lectin-like domain of rTM inactivates ERK, 6 which may blunt the cytoprotective function of rTM.
Other investigators recently showed that a combination of IV and SC injection of rTM effectively blocks the development of MCT-induced SOS in rats and significantly prolongs their survival compared with normal saline-treated rats. 20 They demonstrated that administration of MCT to rats increases serum levels of HMGB1 and non-histone nuclear proteins, and that rTM effectively counteracts the MCT-mediated increase in levels of HMGB1. HMGB1 is released from necrotic cells as well as activated inflammatory cells and stimulates further production of inflammatory cytokines in association with activation of NF-κB. 25, 26 Expression levels of the adhesion molecule ICAM1, which is regulated, at least in part, by HMGB1, were significantly lower in livers removed from rTM-treated rats than in those from normal saline-treated rats. In parallel, fewer neutrophils were noted in livers removed from rTM-treated rats than normal saline-treated rats. 20 The lectin-like domain of TM binds to and degrades HMGB1. 5 In the present experiments, we utilized TME5 lacking the lectin-like domain of TM. The cytoprotective effects mediated by TME5 were powerful enough to alleviate MCT-induced SOS.
TM mitigates radiation-induced bone marrow failure via APC-dependent mechanisms in a murine model. 27 The authors assumed that the TM/APC system protected the bone marrow microenvironment, the so-called niche, from radiation injury and supported hematopoiesis. TME5 could also contribute to cytoprotection of the bone marrow niche in an APC-independent manner.
The cell surface molecules that mediate proangiogenic effects of TM had remained unknown for a long time. Of note, fibroblast growth factor receptor has been recently identified as a candidate receptor for TM. 28 Future experiments will explore whether TME5 exerts the cytoprotective function via fibroblast growth factor receptor. The maximal plasma concentration of TM in the individuals who received a single dose of rTM 380 U/kg (equivalent to 0.06 mg/kg) was 1495.4 ng/ml (~233 nM) with a half-life of 28 h. 29 We previously showed that low dose of rTM (5-50 nM) produced cytoprotective activity. 7 The present study also found that subnanomolar concentrations of TME5 effectively protected endothelial cells from CsA-induced cell damage (Figure 3) .
We have very recently conducted a multi-center clinical trial evaluating the effect of rTM on transplantation-associated coagulopathy after HSCT. Intriguingly, prophylactic use of rTM for transplantation-associated coagulopathy from day 4 to day 14 after HSCT significantly decreased the incidence of GVHD as well as SOS compared with control patients who did not receive rTM. 30 In addition, a pre-clinical study with a murine GVHD model demonstrated that use of rTM increases the population of regulatory T cells in the spleen in conjunction with a decrease in the plasma levels of inflammatory cytokines and significantly prolongs the survival of HSCT-received mice. 31 One of several other explanations could relate to TME5; rTM could alleviated inflamed immune cells via TME5. The first step of developing GVHD relates to destruction of the intestinal mucosa, which leads to bacterial translocation from the intestine to systemic circulation. 32 The cytoprotective action of TME5 could have a role in maintaining the integrity of the intestinal mucosa barrier function and preventing GVHD. Future experiments will investigate the prophylactic effect of TME5 against GVHD in a murine model.
Taken together, the cytoprotective function of TM is localized in TME5. Use of TME5 may be a promising strategy against transplantation-associated complications such as SOS and TMA.
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